Fighting against the global diabetes epidemic with Israeli innovation


Diabetes and its devastating complications are a growing global epidemic. As a serious public health problem, diabetes has the potential to take over the lives of patients and impose higher prices for the world health system.

About 425 million adults worldwide are suffering from diabetes, and the number will increase to 522 million in 2030 and 629 million by 2045, according to estimates by International Diabetes Federation (IDF). At present, an extraordinary 12% of all health care costs for adults are linked to diabetes.

World Diabetes Day, made by the IDF and the World Health Organization in 1991, is celebrated every year on November 14, Sir Frederick Banting's birthday, the famous Canadian scientist who discovered insulin in 1922, and seeks to raise public and political awareness about the problem diabetes.

While there is currently no cure for type 1 or type 2 diabetes, various innovative Israeli medical technologies are changing the rules of the game for diabetics.

Although diabetes is often associated with insulin injection, Oramed Pharmaceuticals, based in Jerusalem, has developed an innovative oral insulin capsule that turns injection treatments into oral therapy. Capsules, for both types of diabetes, are currently in advanced clinical trials from the Food and Drug Administration.

"We have something that can help hundreds of millions of people worldwide," he said. The Jerusalem Postthat executive director and co-founder of Oramed, Nadav Kidron.

Kidron grows in a house where diabetes is always part of the conversation. His mother, Miriam, worked for almost 20 years in the Diabetes Unit at the Hadassah Hebrew University Medical Center.

Together with the Nobel Prize winner, Prof. Avram Hershko, they developed a previously unimaginable solution that allows proteins, such as insulin, to be given orally and intact in the liver, an organ that regulates insulin secretion in the bloodstream. .

"Instead of treating excess glucose in the blood, we interfere with production at the source. This is a far more physiological way to treat diabetes. The vision is that a new paradigm of treatment for diabetics is diet, exercise, oral insulin and, finally, insulin injection," said Kidron.

The current administration of oral therapeutic injections for conditions, including diabetes, also offers clear benefits for the patient's lifestyle.

"There must be a world that suppresses the point where patients depend on insulin, which is also much more expensive. The dream is to see children and adults who smile because they can have a better lifestyle that can be cheaper, and they and the community will much happier. "

In November 2015, Oramed signed a license and investment agreement worth up to $ 50 million with the Chinese HTIT investment and incubation company to obtain exclusive rights to market insulin capsules of companies in China, Hong Kong and Macau. Kidron anticipates that its products will be registered in China rather than in the United States.

"The East has overtaken the West. There are 100 million diabetics in China, but the problem is two thirds are not diagnosed," Kidron said. "Because of the adoption of unhealthy lifestyles and because of the number of patients who are not diagnosed at this time, there is great fear about how they will treat diabetes."

The Oramed platform can take the injected protein and give it orally instead. At present, the company is working on other products, including the GLP-1 analogue, which causes people to lose weight and stimulate insulin production. Last month, Oramed enrolled his first patient in a clinical study of his oral insulin capsule exploration in the treatment of nonalcoholic steatohepatitis (NASH), an advanced form of nonalcoholic fatty liver disease.

"Once you find a way to send it, you don't need to question whether the medicine works. Here we know that the medicine works," according to Dr. Mark Hasleton, Vice President of Business Development at Oramed.

"It has been proven that insulin works, and now we have shown that the platform also works. This is the progress of developing drugs that are far more risk-free. People have been trying for a hundred years, but no one has gone as far as Oramed."

DarioHealth Corp, based in Cesaca, has taken advantage of big data to develop new methods for managing chronic disease data so that people can personalize the management of self-managed diabetes. Dario's pocket blood glucose monitoring system is synchronized with the smartphone application Smart Diabetes Management companies to measure, record and track blood glucose levels.

The DarioHealth blood glucose monitoring system is synchronized with the company's Intelligent Diabetes Management Platform. (Photo: PR)

In addition to recording blood glucose measurements automatically, the GPS location function incorporated in the application allows the pharmacy to communicate with patients in the event of an emergency due to hypoglycemia (low blood sugar).

"The digital diabetes platform is a revolution. A user can, for the first time, be more aware of their condition," said the finance director of PT DarioHealth, Zvi Ben-David, on Post.

"This is because we provide a platform with the ability not only to accurately measure individual statistics, but also from all additional relevant data to understand how their diabetes develops."

DarioHealth announced on Tuesday that its diabetes platform will be launched to 4.6 million customers at 214 Giant Eagle American supermarket pharmacies.

Platform DarioHealth it also provides a food database and information about physical activity, in addition to offering an "A1C" calculator, the most important measure for measuring diabetes control.

"A1C is a measure that is evaluated quarterly with a blood test, but we can estimate it accurately through ongoing measurements sent by individuals," Ben-David said.

DarioHealth announced on Tuesday that its diabetes platform will reach 4.6 million customers at 214 American Giant Eagle supermarket pharmacies.

"Our platform provides pharmacies with access to data online and in real time for each user and allows them to communicate with people when they need it and give them immediate assistance," Ben-David said.

"It's about changing the way people with diabetes are fully monitored: giving care to people when they need it and not when they get to the doctor."


Source link